We are of course aware of the recent coverage in the Daily Mail and Guardian about whether doing the SARS-Cov2 (COVID-19) IgG Antibody Test is valid on a finger-prick sample. Our partner laboratory has done extensive testing to check whether the results are the same between venous samples and finger prick samples and have found that the results are virtually identical.
The method we used to validate was by having volunteers donate venous samples and capillary samples (ie finger-prick) at the same time. We tested both these samples and compared the results and found them to be exactly the same from a clinical/statistical point of view.
Contrary to press reports; our partner laboratory has not been advised that they must stop processing finger-prick/capillary samples and they are continuing to process any samples that we send them.
They are in contact with the MHRA who are in receipt of their validation data and approvals of the kits (CE mark etc) that are sent out. The MHRA is currently assessing their view of the entire industry and our partner laboratory awaits their decision.
At the moment it seems unlikely that MHRA and/or PHE will actually proceed to ban the processing of finger-prick samples as there is absolutely no scientific, clinical or ethical reason for this to be done – but government departments are overworked and get pressures for reasons other than patient care so we will have to wait and see - we have heard that there may not be a decision for several weeks.
Should our partner laboratory be eventually unable to process and report on results of finger-prick blood samples all of our clients are of course entitled to either a 100% refund or a vacutainer kit for venous sampling, and assistance in finding a phlebotomist, but for now it is “business as usual” with Blue Horizon and our partner laboratory – our relationship is with our private patients who will always be put first.